Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 040457 | Registry Identifier | Ethics committee of Faculty of Medicine, Alexandria university, Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Trivalent chromium has shown good results in abolishing inflammation and had a successful result in treating animal model of rheumatoid arthritis. In addition to that, trivalent chromium lacks many side effects which are related to the already known medications of the disease.
So this study aims to evaluate the efficacy of trivalent chromium supplementation in rheumatoid arthritis treatment and measuring the outcomes of that in rheumatoid arthritis patients.
Rheumatoid arthritis is a debilitating autoimmune disease which is treated by medications that have many side effects. Trivalent chromium, a naturally occurring element with regulatory effects on blood sugar, has shown anti-inflammatory properties in many studies and has shown a good response at alleviation of rheumatoid arthritis in the disease animal model. For these reasons trivalent chromium should be tried in rheumatoid arthritis patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Trivalent chromium | Active Comparator | A dietary supplement already available in market one of its known uses is to control diabetes. |
|
| Immunesuppressants | Active Comparator | Synthetic and/ or biological DMARDs |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Trivalent chromium versus synthetic and/ or biological DMARDs | Drug | Supplement and immunesuppressants |
|
| Measure | Description | Time Frame |
|---|---|---|
| Arthritis scored by DAS28 score | DAS 28 is a score of arthritis | three months |
| ESR in mm/hr | lab measures for disease activity | three months |
| CRP mg/dL | lab measures for disease activity | three months |
| Radiological investigations if required (X-RAY, ultrasound, MRI, bone scan) | To assess joints and bone | three months |
| Measure | Description | Time Frame |
|---|---|---|
| Serum urea | A renal function test to exclude trivalent chromium side effects. | three months |
| serum creatinine | A renal function test to exclude trivalent chromium side effects. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Faculty of Medicine, Alexandria University, Egypt | Alexandria | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35829940 | Background | Hassouna SS, Sheta E, Zaki I, Harby SA, Allam EA. Trivalent chromium supplementation ameliorates adjuvant induced rheumatoid arthritis through up-regulation of FOXP3 and decrease in synovial Cathepsin G expression. Inflammopharmacology. 2022 Dec;30(6):2181-2195. doi: 10.1007/s10787-022-01025-8. Epub 2022 Jul 13. | |
| 39030450 | Derived |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D057126 | Nuclear Receptor Subfamily 4, Group A, Member 2 |
| ID | Term |
|---|---|
| D057093 | Orphan Nuclear Receptors |
| D004268 | DNA-Binding Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| three months |
| SGOT | A liver function test to exclude trivalent chromium side effects. | three months |
| SGPT | A liver function test to exclude trivalent chromium side effects. | three months |
| Hassouna SS, Abdel-Moniem OM. Trivalent chromium versus baricitinib for rheumatoid arthritis treatment: first phase 2/3 randomized controlled trial, is trivalent chromium the upcoming immune-modulator? Inflammopharmacology. 2024 Oct;32(5):3163-3179. doi: 10.1007/s10787-024-01515-x. Epub 2024 Jul 19. |
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D018160 | Receptors, Cytoplasmic and Nuclear |